Mark D. Matteucci

70 year

Health Technology

Finance

Consumer Services

Profile

Dr. Mark D.
Matteucci is Chief Scientific Officer & SVP-Discovery Research at Threshold Pharmaceuticals, Inc. Dr. Matteucci was previously employed as a Director-Bioorganic Chemistry by Gilead Sciences, Inc. He received his undergraduate degree from the Massachusetts Institute of Technology and a doctorate degree from The University of Colorado.

Former positions of Mark D. Matteucci

Companies	Position	End
GILEAD SCIENCES, INC.	Corporate Officer/Principal	31/12/1998
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Chief Tech/Sci/R&D Officer	-

See the detail of Mark D. Matteucci's experience

Training of Mark D. Matteucci

Massachusetts Institute of Technology	Undergraduate Degree
The University of Colorado	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mark D. Matteucci's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
GILEAD SCIENCES, INC.	Health Technology

Private companies	1
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Health Technology